Search
Ensartinib
go.drugbank.com/drugs/DB14860ApprovedInvestigational[A265030] Ensartinib was approved by the FDA for adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not previously … [L53263] Although there was no statistically significant difference in overall survival when compared to [crizotinib], ensartinib demonstrated a statistically significant progression-free survival improvement
Fenoldopam
go.drugbank.com/drugs/DB00800ApprovedA dopamine D1 receptor agonist that is used as an antihypertensive agent. It lowers blood pressure through arteriolar vasodilation.
Etripamil
go.drugbank.com/drugs/DB12605ApprovedInvestigational[A275243, A275248] The nasal formulation of etripamil was first approved by the FDA on December 12, 2025 for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT … ) to sinus rhythm in adults.
Pemigatinib
go.drugbank.com/drugs/DB15102ApprovedInvestigationalgrowth factor receptor 2 (FGFR2) gene fusion or other rearrangements as detected by an FDA-approved test. … It works by inhibiting fibroblast growth factor receptors (FGFRs), which are receptor tyrosine kinases that activate signalling pathways in tumour cells.
Astemizole
go.drugbank.com/drugs/DB00637ApprovedWithdrawnIt was withdrawn from market by the manufacturer in 1999 due to the potential to cause arrhythmias at high doses, especially when when taken with CYP inhibitors or grapefruit juice. … Astemizole is a long-acting, non-sedating second generation antihistamine used in the treatment of allergy symptoms.
Categories: Histamine H1 Antagonists, Non-SedatingParomomycin
go.drugbank.com/drugs/DB01421ApprovedInvestigationalAn oligosaccharide antibiotic produced by various streptomyces. [PubChem]
Synonyms: (1R,2R,3S,4R,6S)-4,6-diamino-2-{[3-O-(2,6-diamino-2,6-dideoxy-beta-L-idopyranosyl)-beta-D-ribofuranosyl]oxy}-3-hydroxycyclohexyl 2-amino-2-deoxy-alpha-D-glucopyranosideBlinatumomab
go.drugbank.com/drugs/DB09052ApprovedInvestigational[A7659,A7660,A254831] Blinatumomab is manufactured by Amgen Inc. and marketed under the brand Blincyto. … It was first approved by the FDA in December 2014 for the treatment of CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in relapsed and refractory patients.
Ziconotide
go.drugbank.com/drugs/DB06283ApprovedInvestigational[L13389] To date, ziconotide is the only calcium channel blocking peptide approved for use by the FDA.[A202835] … [A202829, A202835, A202838, A202841, A202850, A202859, L13389] Ziconotide was granted FDA approval on December 28, 2004 for marketing by TerSera therapeutics LLC. under the name Prialt.
Categories: Analgesics, Non-Narcotic, Calcium Channels, N-TypeNatamycin
go.drugbank.com/drugs/DB00826ApprovedInvestigationalAmphoteric macrolide antifungal antibiotic from Streptomyces natalensis or S. chattanoogensis. It is used for a variety of fungal infections, mainly topically. [PubChem]
International brands: N-MycinTasimelteon
go.drugbank.com/drugs/DB09071ApprovedInvestigationalBy activating melatonin receptors MT1 and MT2 in the suprachiasmatic nucleus of the brain, tasimelteon has been shown to improve sleep by resynchronizing the circadian rhythm through its "non-photic" mechanism … Tasimelteon is currently the only drug available for the treatment of N24HSWD and was granted orphan drug status by the FDA in 2010.
Synonyms: N-{[(1R,2R)-2-(2,3-dihydro-1-benzofuran-4-yl)cyclopropyl]methyl}propanamide